Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features

Launched by UNIVERSITY OF CAGLIARI · Jun 16, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the risk of cancer in patients who have indeterminate thyroid nodules, which are lumps on the thyroid that may or may not be cancerous. The researchers want to find new ways to identify thyroid cancer by looking at various features from blood samples and tissue samples of patients with these nodules. This is important because indeterminate nodules have a small chance of being cancerous, around 15-30%, and better testing could help doctors make more informed decisions.

To participate in this study, you would need to have indeterminate thyroid nodules classified as Class III or IV based on a specific system doctors use (called the Bethesda Classification). Unfortunately, if you have nodules that are already known to be more serious (Class V or VI), or if you have spread of cancer to nearby lymph nodes or other parts of your body, you would not be eligible. This trial is not yet recruiting participants, but once it starts, those who are eligible can expect to contribute to important research that could improve how thyroid nodules are assessed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with indeterminate thyroid nodules (Class III and Class IV according to Bethesda Classification of thyroid nodules)
• Exclusion Criteria:
• • Patients with concomitant thyroid nodules of Bethesda Class V or Class VI
• • Patients with preoperative diagnosis of lymph node metastases of central or lateral neck compartment
• • Patients with distant metastases